Pharmaceutical corporation Roche announced the initiation of a state-of-the-art "AI factory" equipped with numerous cutting-edge Nvidia chips to expedite the innovation of novel pharmaceuticals and diagnostics.
Roche announced an increase in its artificial intelligence capabilities through the acquisition of 2,176 Nvidia Blackwell GPUs, to be utilized in the U.S. and Europe.
This purchase raises the company's total number of GPUs to over 3,500, the largest among pharmaceutical companies.
Roche unveiled this development at Nvidia's GTC conference in San Jose, with the aim of leveraging this advanced technology to expedite the process of discovering, developing, manufacturing, and commercializing therapies.
Roche, a Switzerland-based company with a market capitalization of $340 billion, is renowned for its US subsidiary Genentech's advancements in pharmaceuticals for cancer and immune system disorders. Genentech has developed successful drugs such as Herceptin for breast cancer and Avastin for colon and lung cancer.
In the previous fiscal year, Roche generated revenue of $78 billion based on prevailing exchange rates. Roche's recent declaration comes in the wake of Lilly's earlier announcement of a collaboration with Nvidia for the establishment of a $1 billion AI research center in the San Francisco Bay Area. Lilly has experienced a notable success in utilizing AI technology to enhance the production of its widely-used GLP-1s.
Also Read: JD.com Launches Joybuy in Europe
Pharmaceutical companies and venture capital-funded startups are placing significant investments in the belief that artificial intelligence will revolutionize the processes involved in the discovery, development, and production of new drugs.
There is optimism that AI could lead to the identification of treatments for biological targets previously deemed unfeasible to address, and also expedite the protracted clinical trials timeline.
Given that the creation of a novel medication can entail a billion-dollar investment and a decade-long timeframe, any method to hasten this process is highly sought-after — for patients in immediate need of innovative therapies, as well as for drug manufacturers aiming to monetize their advancements within a limited patent period.
Earlier this year, Roche announced that their artificial intelligence tools had facilitated their scientists in the creation of a tailored molecular structure for oncology therapies 25 percent more rapidly, accomplishing an intricate design that would have been unattainable without the assistance of AI. Furthermore, in the development of a new cancer treatment currently progressing to human trials, scientists incorporated AI to safeguard that the therapy did not elicit an immune system reaction that could potentially diminish its efficacy.
Also Read: EU Weighs Extending Aspides Mission to Hormuz amid Iran Crisis
Roche, a major pharmaceutical company, is employing artificial intelligence for internal purposes and engaging in external collaborations, mirroring the approach of other prominent pharmaceutical companies.
Also Read: EU Pushes to Shift Naval Mission to Protect Strait of Hormuz
An instance of this strategy is evident in their recent collaboration with the venture capital-backed startup Manifold Bio, wherein Roche made an initial payment of $55 million to explore innovative methods of drug delivery to the brain through the utilization of AI technology. The agreement holds the potential for significant financial returns, with the total value of the partnership estimated to reach as high as $2 billion should predetermined research, clinical, and commercial objectives be met.